Literature DB >> 15348984

Lack of radiation optic neuropathy in 72 patients treated for pituitary adenoma.

Alfons C M van den Bergh1, Michiel A Schoorl, Robin P F Dullaart, Anton M van der Vliet, Ben G Szabó, Cees A ter Weeme, Jan-Willem R Pott.   

Abstract

The incidence of radiation optic neuropathy (RON) after external photon beam radiation therapy for nonfunctioning pituitary adenoma (NFA) is not well-studied. Retrospective review of ophthalmological and imaging data in 72 patients with NFA treated between 1985 and 1998 with external beam radiation therapy after surgery Clinical follow-up after radiation therapy had to be at least 18 months. RON was defined as a sudden and profound irreversible visual loss affecting the optic nerve or chiasm A review of previously published cases of RON was then performed. In our cohort, no patient had RON. A total of 11 adequately documented series reports of RON were found in the medical literature on radiation-treated NFAs. The incidence of RON in NFA from these series is 0.53% (95% CI, 0.26%-0.96%). An additional 14 single RON cases have been reported, bringing the total of adequately documented RON cases to 25. RON is a rare complication after external beam radiation therapy for NFA.

Entities:  

Mesh:

Year:  2004        PMID: 15348984     DOI: 10.1097/00041327-200409000-00003

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN: 1070-8022            Impact factor:   3.042


  3 in total

Review 1.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

2.  Catastrophic vision loss from radiation-induced optic neuropathy.

Authors:  Sultan Aldrees; Jonathan A Micieli
Journal:  BMJ Case Rep       Date:  2020-02-26

3.  Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

Authors:  Thomas Charleux; Véronique Vendrely; Aymeri Huchet; Renaud Trouette; Amandine Ferrière; Antoine Tabarin; Vincent Jecko; Hugues Loiseau; Charles Dupin
Journal:  Radiat Oncol       Date:  2022-10-13       Impact factor: 4.309

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.